Atrial fibrillation and heart failure: Natural history and pharmacological treatment

Europace

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Savelieva, Irina ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Angiotensin receptor blockade; Angiotensin converting enzyme inhibition; Antiarrhythmic drug; Anticoagulation; Atrial fibrillation; Atrial remodelling; Epidemiology of atrial fibrillation; Heart failure; Pharmacology of atrial fibrillation

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; AAP 10; ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIARRHYTHMIC PEPTIDE; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CLOPIDOGREL; CP 0605; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; GSMTX 4; HYDRALAZINE; IRBESARTAN; ISOSORBIDE; LOSARTAN; N [1 [4 (4 FLUOROPHENOXY)BUTYL] 4 PIPERIDINYL] N METHYL 2 BENZOTHIAZOLAMINE; NEUROHORMONE; PLACEBO; ROTIGAPTIDE; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; WARFARIN;

ADRENERGIC STIMULATION; AGING; ANTICOAGULATION; ATRIOVENTRICULAR CONDUCTION; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DETERIORATION; DEVELOPED COUNTRY; DISEASE COURSE; HEART ARRHYTHMIA; HEART ATRIUM CONTRACTION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE CONTRACTION; HUMAN; INOTROPISM; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINUS RHYTHM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; PREVALENCE; PROGNOSIS;

EID: 4444299660     PISSN: 10995129     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eupc.2004.07.003     Document Type: Review

References (85)

1. Go A.S. Hylek E.M. Phillips K.A. et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001 285 2370-2375
2. Savelieva I. Camm A.J. Clinical trends in atrial fibrillation at the turn of the millennium. J Intern Med 2001 250 369-372
3. Benjamin E.J. Levy D. Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994 271 840-844
4. Tsang T.S. Gersh B.J. Appleton C.P. et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002 40 1636-1644
5. Cleland J.G.F. Swedberg K. Follath F. et al. for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme e a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003 24 442-463
6. Camm A.J. Savelieva I. Atrial fibrillation: advances and perspectives. Dialog Cardiovasc Med 2003 8 183-202
7. Yusuf S. Pfeffer M.A. Swedberg K. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 362 777-781
8. Klapholz M. Maurer M. Lowe A.M. et al. for the New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004 43 1432-1438
9. Wang T.J. Larson M.G. Levy D. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Study. Circulation 2003 107 2920-2925
10. Dries D.L. Exner D.V. Gersh B.J. et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998 32 695-703
11. Middlekauff H.R. Stevenson W.G. Stevenson L.W. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991 84 40-48
12. Pedersen O.D. Bagger H. Keller N. et al. for the Danish Investigations of Arrhythmia and Mortality ON Dofetilide Study Group. Efficacy of dofetilide in the treatment of atrial fibrillationeflutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 2001 104 292-296
13. Mathew J. Hunsberger S. Fleg J. et al. for the Digitalis Investigation Group. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000 118 914-922
14. Crijns H.J.G.M. Tjeerdsma G. De Kam P.J. et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000 21 1238-1245
15. Carson P.E. Johnson G.R. Dunkman W.B. et al. for the VHeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation 1993 87 102-110
16. Naito M. David D. Michelson E.L. et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983 106 284-291
17. Clark D.M. Plumb V.J. Epstein A.E. Kay G.N. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997 30 1039-1045
18. Francis G.S. Benedict C. Johnstone D.E. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a sub-study of the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 1990 82 1724-1729
19. Vantrimpont P. Rouleau J.L. Ciampi A. et al. for the SAVE Investigators. Two-year time course and significance of neurohumoral activation in the Survival And Ventricular Enlargement (SAVE) Study. Eur Heart J 1998 19 1552-1563
20. Shinbane J.S. Wood M.A. Jensen D.N. et al. Tachycardiainduced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997 29 709-715
21. Allessie M.A. Boyden P.A. Camm A.J. et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001 103 769-777
22. Dauod E.G. Bogun F. Goyal R. et al. Effects of atrial fibrillation on atrial refractoriness in humans. Circulation 1996 94 1600-1606
23. Pandozi C. Baianconi L. Villani M. et al. Electrophysiological characteristics of the human atria after cardioversion of persistent atrial fibrillation. Circulation 1998 98 2860-2865
24. Ausma J. Litijens N. Lenders M.H. et al. Time course of atrial fibrillation-induced cellular structural remodeling in atria of the goat. J Mol Cell Cardiol 2001 33 2083-2094
25. Van der Velden H.M. Ausma J. Rook M.B. et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000 46 476-486
26. Ausma J. Van Der Velden H.M.W. Lenders M.H. et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003 107 2051-2058
27. Satoh T. Zipes D.P. Unequal atrial stretch in dogs increases dispersion of refractoriness conductive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996 7 833-842
28. Li D. Melnyk P. Feng J. et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000 101 2631-2638
29. Bode F. Katchman A. Woosley R.L. Franz M.R. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation 2000 101 2200-2205
30. Saito T. Waki K. Becker A. Left myocardial extension onto pulmonary veins in humans: anatomical observations relevant for atrial arrhythmias. J Cardiovasc Electrophysiol 2000 11 888-894
31. Lin W.S. Prakash V.S. Tai C.T. et al. Pulmonary vein morphology in patients with paroxysmal atrial fibrillation initiated by ectopic beats originating from the pulmonary veins: implications for catheter ablation. Circulation 2000 101 1274-1281
32. Goette A. Staack T. Röcken C. et al. Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000 35 1669-1677
33. Li D. Shinagawa K. Pang L. et al. Effects of angiotensinconverting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachycardiainduced congestive heart failure. Circulation 2001 104 2608-2614
34. Goette A. Lendeckel U. Klein H.U. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002 54 247-258
35. Berk B.C. Angiotensin II receptors and angiotensin IIstimulated signal transduction. Heart Fail Rev 1998 67 653-692
36. Rogg H. de Gasparo M. Graedel E. et al. Angiotensin IIreceptor subtypes in human atrial and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 1996 17 1112-1120
37. Goette A. Arndt M. Röcken C. et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000 101 2678-2681
38. Francis G.S. Benedict C. Johnstone D.E. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a sub-study of the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 1990 82 1724-1729
39. Kumagai K. Nakashima H. Urata H. et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003 41 2197-2204
40. Nakashima H. Kumagai K. Urara H. et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000 101 2612-2617
41. Pedersen O.D. Bagger H. Køber L. et al. for the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999 100 376-380
42. Vermes E. Tardif J.C. Bourassa M.G. et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction. Circulation 2003 107 2926-2931
43. Maggioni A.P. Latini R. Negri M. et al. for the Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in the patients with heart failure in the Val-HeFT trial. Circulation 2003 108 507-508 [abstract]
44. Wachtell K. Lehto M. Hornestam B. et al. Losartan reduces the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. Eur Heart J 2003 24 504 [abstract]
45. Hernandez-Madrid A. Bueno M.G. Rebollo J.G. et al. Use of irbesartan to maintain sinus rhythm in patients with longlasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002 39(106) 331-336
46. Ueng K.C. Tsai T.P. Yu W.C. et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003 24 2090-2098
47. Swedberg K. Pfeffer M. Cohen-Solal A. et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from CHARM. J Am Coll Cardiol 2004 43 222A [abstract]
48. Hohnloser S.H. Kuck K.H. Lilienthal J. for the PIAF Investigators. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000 356 1789-1794
49. Carlsson J. Miketic S. Windeler J. et al. for the STAF Investigators. Randomized trial of rate control versus rhythm control in persistent atrial fibrillation: the Strategies of Treatment in Atrial Fibrillation (STAF) Study. J Am Coll Cardiol 2003 41 1690-1696
50. Opolski G. Torbicki A. Kosior D. et al. Rhythm control versus rate control in patients with persistent atrial fibrillation: the results of the HOT CAFÉ Polish Study. Pol Heart J 2003 59 1-16
51. Van Gelder I.C. Hagens V.E. Bosker H.A. et al., for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 1834-1840
52. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 1825-1833
53. Camm A.J. Savelieva I. Rate versus rhythm control: is the debate over? J Interv Card Electrophysiol 2002 7 7-11
54. Crijns H.J.G.M. Tjeerdsma G. De Kam P.J. et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000 21 1238-1245
55. Fuster V. Rydén L.E. Asinger R.V. et al. Task Force Report: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001 22 1852-1923
56. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004 109 1509-1513
57. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002 Oct 144 597-607
58. Olshansky B. Rosenfeld L.E. Warner A.K. the AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004 43 1201-1208
59. Joglar J.A. Acusta A.P. Schusterman N.H. et al. Effect of carvedilol on survival and haemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the U.S. Carvedilol Heart Failure Trial Program Am. Heart J. 2001 142 498-501
60. Khand A.U. Rankin A.C. Martin W. et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003 42 1944-1951
61. Tumasyan L.R. Nargizyan A.B. Kamalyan H.S. et al. Comparative efficacy of digoxin, bisoprolol and their combination to control ventricular response at rest and during exercise in congestive heart failure and atrial fibrillation. Eur Heart J 2003 24 514 [abstract]
62. Brignole M. Menozzi C. Gianfranchi L. et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomised controlled study. Circulation 1998 98 953-960
63. Weerasooriya R. Davis M. Powell A. et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003 41 1697-1702
64. McMurray J.J. Dargie H.J. Ford I. et al. Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: evidence form the CAPRICORN study. Circulation 2001 104 II-700 [abstract]
65. Lechat P. Hulot J.S. Escolano S. et al. on behalf of the CIBIS II Investigators. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001 103 1428-1433
66. Roy D. Talajic M. Dorian P. et al. for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000 342 913-920
67. Deedwania P.C. Singh B.N. Ellenbogen K. for the Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHFSTAT). Circulation 1998 98 2574-2579
68. Touboul P. Brugada J. Capucci A. et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study Eur Heart J 2003 24 1481-1487
69. Connolly S.J. Schnell D.J. Page R.L. et al. Doseeresponse relations of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am J Cardiol 2001 88 974-979
70. Pratt C.M. Singh S. Al-Khalidi H.R. et al. on behalf of the ALIVE Investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004 43 1211-1216
71. Camm A.J. Pratt C.M. Schwartz P.J. et al. Azimilide Post Infarct Evaluation (ALIVE): azimilide does not affect mortality in post-myocardial infarction patients. Circulation 2004 109 990-996
72. Savelieva I. Camm A.J. Update on antiarrhythmic treatment of atrial fibrillation. In: Tse HF, Lee KLF, Lau CP, editors. Clinical cardiac pacing and electrophysiology. Bologna, Italy: Monduzzi Editore 2003 p. 923-944
73. Polontchouk L. Haefliger J.A. Ebelt B. et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001 38 883-891
74. Muller A. Gottwald M. Tudyka T. et al. Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 1997 327 65-72
75. Dhein S. Polontchouk L. Salameh A. Haefliger J.A. Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40. Biol Cell 2002 94 409-422
76. Elias C.L. Lukas A. Shurraw S. et al. Inhibition of NaC/Ca2C exchange by KB-R7943: transport mode selectivity and antiarrhythmic consequences. Am J Physiol Heart Circ Physiol 2001 281 H1334-H1345
77. Kamath S. Blann A.D. Chin B.S. Lip G.Y.H. Platelet ctivation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart 2003 89 1093-1095
78. Baker D.W. Wright R.F. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. J Am Med Assoc 1994 272 1614-1618
79. Strauss S.E. Majumdar S.R. McAlister F.A. New evidence for stroke prevention: scientific review. JAMA 2002 288 1388-1395
80. Hart R.G. Benavente O. McBride R. Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 131 492-501
81. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 1449-1457
82. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998 279 1273-1277
83. Albers G.W. Dalen J.E. Laupacis A. et al. Antithrombotic therapy in atrial fibrillation. Chest 2001 119 194S-206S
84. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from three clinical trials. Arch Intern Med 1998 158 1316-1320
85. Go A.S. Hylek E.M. Borowsky L.H. et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999 131 927-934